Shanxi Zhendong Pharmaceutical Co., Ltd. Class A

Shanxi Zhendong Pharmaceutical Co., Ltd. Class A

SSZSE:300158
4.49
CNY
-0.11
(-2.39%)
-1.37EPS
4.42BMarket Cap

Total Valuation

CNY

As of June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A carries a market capitalization of 4.42B, placing it among publicly traded companies globally. Its enterprise value stands at 3.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.42B
Enterprise Value3.36B

Share Statistics

As of June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A has 1.01B shares outstanding.

Shares Outstanding1.01B

Valuation Ratios

These figures are as of June 30, 2025. The price-to-sales ratio is 1.49, and the price-to-book ratio stands at 1.21.

PS Ratio1.49
PB Ratio1.21
P/TBV Ratio1.36

Enterprise Valuation

These figures are as of June 30, 2025. The EV/Sales ratio of 1.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.36B versus a market cap of 4.42B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.15

Financial Position

As of June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.07, indicating conservative leverage, while an interest coverage ratio of -259.75 demonstrates limited ability to service its debt obligations.

Current Ratio3.19
Quick Ratio1.22
Debt / Equity0.07
Interest Coverage-259.75

Financial Efficiency

CNY

Over the twelve months ended June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A posted a negative return on equity (ROE) of -30.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.93, reflecting losses generated across the asset base. The company generates approximately 793,015.02 in revenue per employee across its workforce of 3,684.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.71 indicates how many times Shanxi Zhendong Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-30.84
Return on Assets (ROA)-25.93
Revenue Per Employee793,015.02
Employee Count3,684.00
Inventory Turnover1.71

Taxes

CNY

Over the twelve months ended June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A recorded 19.67M in income tax expense. The company reported a pretax loss of -1.33B and -1.35B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax19.67M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A's stock has declined approximately 37.55% over the past 52 weeks. The 50-day moving average sits at 5.05, while the 200-day moving average is 5.43.

52-Week Price Change-37.55%
50-Day Moving Average5.05
200-Day Moving Average5.43

Income Statement

CNY

Over the twelve months ended June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A generated 2.92B in revenue and converted that into -1.35B in net income, yielding earnings per share of -1.37. EBITDA reached -732.59M, while operating income came in at -328.56M.

Revenue2.92B
Gross Profit1.41B
Operating Income-328.56M
Pretax Income-1.33B
Net Income-1.35B
EBITDA-732.59M
EBIT-732.59M
Earnings Per Share (EPS)-1.37

Balance Sheet

CNY

As of June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A holds 1.03B in cash and equivalents against 2.51M in total debt, resulting in a net debt position of -439.20M. Total book value stands at 3.66B, with working capital of 1.84B providing operational flexibility.

Cash & Cash Equivalents1.03B
Total Debt2.51M
Net Debt-439.20M
Equity (Book Value)3.66B
Book Value Per Share3.64
Working Capital1.84B

Cash Flow

CNY

These figures cover the twelve months ended June 30, 2025.

Capital Expenditures-225.53M

Margins

Over the twelve months ended June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A posted a gross margin of 48.26, reflecting its pricing power and cost economics. The operating margin of -11.25 and net profit margin of -46.25 provide insight into operational efficiency.

Gross Margin48.26
Operating Margin-11.25
Pretax Margin-45.69
Profit Margin-46.25
EBITDA Margin-25.08

Dividends & Yields

Over the twelve months ended June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.02 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.45, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanxi Zhendong Pharmaceutical Co., Ltd. Class A shareholders.

Payout Ratio-0.02
Shareholder Yield0.45

Stock Splits

Shanxi Zhendong Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 14, 2018 with a 1:2 split ratio.

Last Split Date6/14/2018
Split Ratio1:2

Scores

As of June 30, 2025, Shanxi Zhendong Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 3.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.53